(Q33688784)

28 July 2017

1 reference

title

Does levodopa accelerate Parkinson's disease? (English)

1 reference

28 July 2017

1 reference

1 reference

2

Stern MB

1 reference

28 July 2017

Simuni T

1

1 reference

28 July 2017

publication date

1 June 1999

1 reference

28 July 2017

1 reference

28 July 2017

volume

14

1 reference

28 July 2017

issue

6

1 reference

28 July 2017

page(s)

399-408

1 reference

Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease

28 July 2017

cites work

1 reference

12 December 2020

Parkinsonism: onset, progression, and mortality

1 reference

12 December 2020

Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase

1 reference

12 December 2020

Intense oxidative DNA damage promoted by L-dopa and its metabolites. Implications for neurodegenerative disease

1 reference

12 December 2020

The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: role of early treatment and disease progression

1 reference

12 December 2020

Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants.

1 reference

12 December 2020

Possible role of neuromelanin in the pathogenesis of Parkinson's disease

1 reference

12 December 2020

Long-term treatment of Parkinson's disease with bromocriptine

1 reference

12 December 2020

Oxidants, antioxidants, and the degenerative diseases of aging

1 reference

12 December 2020

Toxic and protective effects of L-dopa on mesencephalic cell cultures

1 reference

12 December 2020

Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease

1 reference

12 December 2020

1 reference

12 December 2020

Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line

1 reference

12 December 2020

The oxidant stress hypothesis in Parkinson's disease: evidence supporting it

1 reference

12 December 2020

Twin studies and the genetics of Parkinson's disease--a reappraisal

1 reference

12 December 2020

Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia

1 reference

12 December 2020

Histochemical detection of apoptosis in Parkinson's disease.

1 reference

12 December 2020

Free radicals in medicine. I. Chemical nature and biologic reactions

1 reference

12 December 2020

L-dopa increases nigral production of hydroxyl radicals in vivo: potential L-dopa toxicity?

1 reference

12 December 2020

Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions

1 reference

12 December 2020

The endogenous toxin hypothesis of the etiology of Parkinson's disease and a pilot trial of high-dosage antioxidants in an attempt to slow the progression of the illness

1 reference

12 December 2020

Parkinsonism treated with levodopa: progression and mortality.

1 reference

12 December 2020

Exposure of striatal [corrected] synaptosomes to L-dopa increases levels of oxidized glutathione.

1 reference

12 December 2020

Levodopa: is toxicity a myth?

1 reference

12 December 2020

The epidemiology of Parkinson's disease. A case-control study of young-onset and old-onset patients

1 reference

12 December 2020

Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics

1 reference

12 December 2020

New insights into the cause of Parkinson's disease

1 reference

12 December 2020

Nigrostriatal Dopaminergic Neurons Remain Undamaged in Rats Given High Doses of l-DOPA and Carbidopa Chronically

1 reference

12 December 2020

Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine

1 reference

12 December 2020

Oxidative stress in neurodegenerative diseases

1 reference

12 December 2020

Oxygen radicals and human disease

1 reference

12 December 2020

Dopamine neurotoxicity: inhibition of mitochondrial respiration

1 reference

12 December 2020

Parkinson's disease in 65 pairs of twins and in a set of quadruplets

1 reference

12 December 2020

Monoamine oxidase, dopamine and Parkinson's disease

1 reference

12 December 2020

Epidemiology of parkinsonism: Incidence, classification, and mortality

1 reference

12 December 2020

Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations.

1 reference

12 December 2020

Chronic levodopa impairs morphological development of grafted embryonic dopamine neurons

1 reference

12 December 2020

Update on the management of Parkinson's disease

1 reference

12 December 2020

Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?

1 reference

12 December 2020

Does levodopa aggravate Parkinson's disease?

1 reference

12 December 2020

Metabolic modification of some neurologic disorders

1 reference

12 December 2020

Parkinson's disease: a disorder due to nigral glutathione deficiency?

1 reference

12 December 2020

Levodopa induces apoptosis in cultured neuronal cells--a possible accelerator of nigrostriatal degeneration in Parkinson's disease?

1 reference

12 December 2020

COHORT ANALYSIS OF PARKINSON'S SYNDROME: EVIDENCE FOR A SINGLE ETIOLOGY RELATED TO SUBCLINICAL INFECTION ABOUT 1920.

1 reference

12 December 2020

Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period

1 reference

12 December 2020

Mitochondrial complex I deficiency in Parkinson's disease

1 reference

12 December 2020

The significance of the Lewy body in the diagnosis of idiopathic Parkinson's disease

1 reference

12 December 2020

Clinical pharmacokinetics of anti-parkinsonian drugs

1 reference

12 December 2020

Managing the late complications of Parkinson's disease

1 reference

12 December 2020

The effects of combining carbidopa with levodopa for Parkinson's disease

1 reference

12 December 2020

Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.

1 reference

12 December 2020

Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson's disease

1 reference

12 December 2020

L-dopa inhibits complex IV of the electron transport chain in catecholamine-rich human neuroblastoma NB69 cells

1 reference

12 December 2020

Dopamine induces apoptotic cell death of a catecholaminergic cell line derived from the central nervous system.

1 reference

12 December 2020

Neurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron/cortical astrocyte cocultures.

1 reference

12 December 2020

L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress.

1 reference

12 December 2020

1 reference

12 December 2020

A rationale for dopamine agonists as primary therapy for Parkinson's disease

1 reference

12 December 2020

Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones

1 reference

12 December 2020

Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease

1 reference

12 December 2020

Effects of enhanced striatal dopamine turnover in vivo on glutathione oxidation

1 reference

12 December 2020

Environmental factors in the etiology of Parkinson's disease.

1 reference

12 December 2020

Dopamine and norepinephrine uptake and metabolism by astroglial cells in culture

1 reference

12 December 2020

Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy

1 reference

12 December 2020

Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture.

1 reference

12 December 2020

Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease

1 reference

12 December 2020

Carbidopa in Parkinson disease and in nausea and vomiting of levodopa

1 reference

12 December 2020

Astrocytes protect neurons from hydrogen peroxide toxicity

1 reference

12 December 2020

The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence

1 reference

12 December 2020

Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.

1 reference

12 December 2020

Does levodopa therapy delay death in Parkinson's disease? A review of the evidence.

1 reference

12 December 2020

Aetiology of Parkinson's disease

1 reference

12 December 2020

The detrimental effect of levodopa on behavioral efficacy of fetal dopamine neuron grafts in rats is reversible following prolonged withdrawal of chronic dosing

1 reference

12 December 2020

Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease.

1 reference

12 December 2020

Mitochondrial complex I deficiency in Parkinson's disease

1 reference

12 December 2020

Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity

1 reference

12 December 2020

Levodopa, fertility, and longevity

1 reference

12 December 2020

Oxidative stress as a cause of Parkinson's disease

1 reference

12 December 2020

Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease

1 reference

12 December 2020

Is levodopa toxic to human substantia nigra?

1 reference

12 December 2020

Glia conditioned medium protects fetal rat midbrain neurones in culture from L-DOPA toxicity.

1 reference

12 December 2020

Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease

1 reference

12 December 2020

1 reference

12 December 2020

Mortality associated with early and late levodopa therapy initiation in Parkinson's disease

1 reference

12 December 2020

10.2165/00002512-199914060-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

28 July 2017

1009140925

0 references

1 reference